The First Crispr Treatment Is Making Its Way to Patients
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
EurekAlert!3d
Indonesian Thalassemia Survivor: "I've broken the inheritance chain of thalassemia"
Stanley Joewono is an Indonesia social media influencer and exercise enthusiast. Diagnosed with thalassemia at just 8 months ...
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...
manilatimes1d
Two New Solutions from Hemex Health Empower More Clinicians and Health Workers to Test for Iron Deficiency Anaemia and Sickle Cell Disease
A next generation Snap Cartridge, part of the Gazelle™ S-10B Hb Variant Test Multipack, will simplify sample preparation so ...
FiercePharma10d
Vertex's Casgevy breaks ground with 1st commercial patient infusions as company readies another major launch for 2025
With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...
Agios Pharmaceuticals to present new data on mitapivat, tebapivat
Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company’s PK activators, will be featured in ...